Naimish Patel - 28 May 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: Chief Medical Officer
Issuer ticker: CRSP
Reported as of: 28 May 2026
Net transaction value: -$210,577
SEC form: 4
Accepted by SEC: 01 Jun 2026, 17:35:40 UTC
Prior SEC filing: 24 Mar 2026
Next SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

Naimish Patel filed Form 4 for CRISPR Therapeutics AG (CRSP) on 01 Jun 2026.

Key facts

This page summarizes Naimish Patel's Form 4 filing for CRISPR Therapeutics AG (CRSP).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Jun 2026, 17:35.

Change

Previous filing in this sequence was filed on 24 Mar 2026.
Current net transaction value: -$210,577.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002021679 Primary reporting owner

Patel Naimish

Relationship: Chief Medical Officer
Address: C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON
Signature: Elizabeth Ryland Waldinger, attorney-in-fact
Signature date: 01 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRSP transaction

Common Shares

Options Exercise

Transaction value
Shares: +10,000
Change %: +76%
Price
Shares after: 23,143
Date: 28 May 2026
Ownership: Direct
Footnotes: F1

CRSP transaction

Common Shares

Sale

Transaction value: $210,577
Shares: -3,786
Change %: -16%
Price: $55.62
Shares after: 19,357
Date: 29 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -10,000
Change %: -33%
Price
Shares after: 20,000
Date: 28 May 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 10,000
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Footnote F2

Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Footnote F3

This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.